These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7141263)

  • 21. Combination chemotherapy for advanced endometrial adenocarcinoma.
    Deppe G; Bruckner HW; Cohen CJ
    Int J Gynaecol Obstet; 1980; 18(3):168-9. PubMed ID: 6109646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytologic evaluation of exclusive medroxyprogesterone acetate treatment for vaginal recurrence of endometrial adenocarcinoma.
    Bonte J; Drochmans A; Ide P
    Acta Cytol; 1970 May; 14(5):353-6. PubMed ID: 5284269
    [No Abstract]   [Full Text] [Related]  

  • 23. [New technic of pre-surgical medical treatment of adenocarcinoma of the endometrium].
    Martella E; Torella M; Messalli EM; Quirino R
    Arch Ostet Ginecol; 1978; 83(3-4):81-91. PubMed ID: 757771
    [No Abstract]   [Full Text] [Related]  

  • 24. [Therapy of advanced endometrial cancer].
    Okada H; Yamamoto T
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1848-55. PubMed ID: 2144105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progestins in the treatment of endometrial carcinoma.
    Anderson DG
    Surg Forum; 1965; 16():398-400. PubMed ID: 5835208
    [No Abstract]   [Full Text] [Related]  

  • 26. [Estrogen and progesterone receptors in endometrial carcinoma during high-dose progestogen (Depo-Provera) therapy].
    Thurzó L; Sas M; Falkay G
    Orv Hetil; 1986 Oct; 127(43):2613-6. PubMed ID: 2947029
    [No Abstract]   [Full Text] [Related]  

  • 27. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
    Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
    Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progestins in the treatment of patients with endometrial adenocarcinoma.
    Smith JP; Rutledge F; Soffar SW
    Am J Obstet Gynecol; 1966 Apr; 94(7):977-84. PubMed ID: 5910365
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cell surface changes after high-dosage progesterone treatment in endometrial carcinoma].
    Szarvas Z; Zsolnai B
    Zentralbl Gynakol; 1984; 106(14):1010-7. PubMed ID: 6239468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Beneficial effects of contraceptive doses and large doses of medroxyprogesterone in the prevention and treatment of uterine hyperplasia].
    Bonte J
    Gynakol Rundsch; 1978; 18(3-4):172-82. PubMed ID: 569622
    [No Abstract]   [Full Text] [Related]  

  • 31. The treatment of uterine adenocarcinoma with medroxyprogesterone acetate.
    Horger EO; Williamson HO; Hester LL
    J S C Med Assoc; 1966 Jun; 62(6):217-23. PubMed ID: 5227728
    [No Abstract]   [Full Text] [Related]  

  • 32. [Combination with medroxyprogesterone acetate and chemotherapy making possible complete removal of uterine corpus carcinoma].
    Tajima H; Okada T; Fujimori Y; Tomioka Y; Hirano M; Yoshida T; Ikeda S; Hata T
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2461-4. PubMed ID: 2526620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaginal cytologic evaluation as a practical link between hormone blood levels and tumor hormone dependency in exclusive medroxyprogesterone treatment of recurrent or metastatic endometrial adenocarcinoma.
    Bonte J; Decoster JM; Ide P
    Acta Cytol; 1977; 21(2):218-24. PubMed ID: 266331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Apparent cure with a progestagen of endometrial cancer with pulmonary metastases].
    Legrand M; Eukirch
    Nouv Presse Med; 1976 Oct; 5(32):2086. PubMed ID: 980740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of adenocarcinomas of the uterine body with medroxyprogesterone].
    Bonte J; Drochmans A; Lassance M
    Gynecol Obstet (Paris); 1966; 65(2):179-85. PubMed ID: 5942790
    [No Abstract]   [Full Text] [Related]  

  • 36. Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic or recurrent endometrial carcinoma. Preliminary report.
    Piver MS; Lele S; Barlow JJ
    Obstet Gynecol; 1980 Sep; 56(3):370-2. PubMed ID: 7422177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of medroxyprogesterone (MAP) therapy on the DNA content in adenocarcinoma of the human endometrium].
    Vecchietti G; Gerzeli G; Zanoio L; Novelli GG; Barni S
    Minerva Ginecol; 1979; 31(7-8):597-603. PubMed ID: 481819
    [No Abstract]   [Full Text] [Related]  

  • 38. Proceedings: Vaginal cytologic evaluation as a predictive test on hormone dependency and responsiveness to progestogens of endometrial adenocarcinoma.
    Ide P; Bonte J
    Br J Cancer; 1974 Aug; 30(2):175. PubMed ID: 4419502
    [No Abstract]   [Full Text] [Related]  

  • 39. Medroxyprogesterone in the management of primary and recurrent or metastatic uterine adenocarcinoma.
    Bonte J
    Acta Obstet Gynecol Scand Suppl; 1972; 19():21-4. PubMed ID: 4508284
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of the mechanism of action of a progestin on endometrial andenocarcinoma.
    Anderson DG
    Surg Forum; 1969; 20():411-3. PubMed ID: 5376941
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.